Research Use Only. The information presented here is for scientific and educational purposes. These compounds are not intended for human consumption, self-administration, or therapeutic use.
Introduction
Semax is a synthetic heptapeptide that has become a recurring subject of neuropeptide research, especially in studies of brain-derived neurotrophic factor (BDNF) and the wider neurotrophic signaling system. It is structurally derived from ACTH(4-10), a fragment of adrenocorticotropic hormone, and was first developed and characterized by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike the parent hormone, Semax is studied for its actions on the central nervous system without the classical steroid-stimulating role of full-length corticotropin.
This article reviews the studied Semax mechanism, focusing on how the peptide is investigated for its interaction with neurotrophic factors and downstream signaling cascades in preclinical, in-vitro, and animal research. Every attribute described here reflects laboratory findings only; these materials are for research use only, not for human consumption. Readers comparing compounds within the nootropic category can review the broader research peptide catalog alongside the specific Semax research listing for identity and documentation details.
What Is Semax? Molecular Identity and ACTH(4-10) Origins
Semax belongs to a family of short regulatory peptides modeled on natural fragments of adrenocorticotropic hormone (ACTH). The native ACTH(4-10) sequence spans seven residues, and Semax preserves the first four of these, Met-Glu-His-Phe, which correspond to the ACTH(4-7) region. To this core the molecule appends a Pro-Gly-Pro (PGP) tripeptide at the C-terminus, producing a stable heptapeptide that behaves very differently from the intact hormone.
From Corticotropin Fragment to Stabilized Peptide
The Pro-Gly-Pro extension is the defining design feature of the peptide. Free ACTH fragments are broken down rapidly by peptidases, which limits how long they persist in an experimental system. The added PGP motif is reported to slow this enzymatic degradation substantially, giving Semax a longer window of measurable activity in research models. Because the retained fragment lacks the residues responsible for stimulating adrenal steroid output, Semax is examined as a neuroactive peptide rather than a hormone that drives cortisol release. This separation of neurotrophic signaling from endocrine activity is a central reason the compound is used as a research probe.
Molecular Identity at a Glance
The values below reflect commonly reported laboratory attributes and are provided for comparison only.
| Attribute | Reported value |
|---|---|
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Sequence length | 7 residues (heptapeptide) |
| Molecular formula | C37H51N9O10S |
| Approximate molecular weight | 813.9 g/mol |
| Structural class | Synthetic ACTH(4-10)-derived neuropeptide |
| Parent fragment | ACTH(4-7), Met-Glu-His-Phe |
| Stabilizing motif | C-terminal Pro-Gly-Pro (PGP) |
The BDNF and TrkB Signaling Pathway
The most studied element of the Semax mechanism is its relationship with brain-derived neurotrophic factor. BDNF is a member of the neurotrophin family that supports neuronal survival, differentiation, and synaptic plasticity, and it is one of the most closely watched readouts in preclinical models of learning and neural repair. Semax is characterized in the literature as an indirect modulator of this system rather than a direct agonist of a single receptor.
BDNF Upregulation in Preclinical Models
In rodent studies, Semax has been reported to raise levels of BDNF protein and BDNF messenger RNA in brain regions including the hippocampus and basal forebrain. Work published by Dolotov and colleagues in 2006 described specific binding of the peptide together with an associated increase in BDNF within the rat basal forebrain, a finding that has anchored much of the subsequent mechanistic literature. Later transcriptome analyses reported that Semax shifts the expression of numerous genes tied to the neurotrophin, vascular, and immune systems, especially under conditions modeling reduced cerebral blood flow.
proBDNF, Mature BDNF, and the TrkB Receptor
BDNF is first produced as a precursor, proBDNF, before being processed into its mature form. Mature BDNF signals mainly through the high-affinity receptor TrkB (tropomyosin receptor kinase B), activating pathways associated with cell survival and plasticity, whereas proBDNF interacts with the p75 receptor and can drive opposing responses. Semax research examines how the peptide influences this balance, including reported changes in TrkB expression that accompany the rise in BDNF. Because the downstream TrkB cascade touches signaling routes such as MAPK and PI3K/Akt, even small shifts in neurotrophin availability are of interest to researchers mapping synaptic plasticity.
The Wider Neurotrophic Cascade
BDNF is the headline finding, but the studied Semax mechanism extends across several neurotrophic and enzymatic routes. This breadth is part of why the peptide is treated as a system-level modulator in research rather than a narrow single-target ligand.
NGF and Nerve Growth Factor Signaling
Studies also report changes in nerve growth factor (NGF), a second major neurotrophin, along with its associated signaling genes. By modulating both BDNF and NGF, Semax is described in the literature as a broad influence on the neurotrophin system. Researchers evaluating identity and purity before such experiments often consult a supplier certificate and follow guidance on how to read a peptide COA, since short peptides are sensitive to synthesis quality and storage.
Enzyme Modulation and Neuroprotection Research
Beyond direct neurotrophin expression, Semax is studied for its effect on enkephalin-degrading enzymes. By slowing the breakdown of endogenous regulatory peptides, the compound may indirectly prolong their signaling within an experimental system. In preclinical models of cerebral ischemia, investigators have examined whether Semax-associated increases in neurotrophic factors correspond to protective changes in neural tissue. These observations are drawn strictly from animal and cell-culture settings and are not evidence of any human outcome.
Semax Among Related Research Peptides
Placing Semax beside neighboring compounds helps clarify what is distinctive about its studied mechanism. The peptide is frequently compared with Selank, another short Russian-developed neuropeptide that shares the Pro-Gly-Pro stabilizing motif but originates from a different parent molecule. Researchers evaluating either compound can review the Selank research listing for a direct identity comparison, and can extend their due diligence with broader supplier vetting practices that support reproducible work.
The following comparison reflects commonly reported laboratory attributes and is provided for comparison only.
| Peptide | Length | Primary studied pathway | Research class |
|---|---|---|---|
| Semax | 7 aa | BDNF, TrkB, and NGF neurotrophic signaling | ACTH(4-10)-derived neuropeptide |
| Selank | 7 aa | GABAergic tone and BDNF modulation | Tuftsin analog neuropeptide |
| ACTH(4-10) | 7 aa | Attention and melanocortin research | Native corticotropin fragment |
Frequently Asked Questions
What is the mechanism of action of Semax?
In research settings, Semax is studied as a regulatory neuropeptide that interacts with the neurotrophin system rather than acting through a single classical receptor. Investigations report that Semax influences the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), and that it may slow the breakdown of endogenous regulatory peptides by modulating enkephalin-degrading enzymes. These observations come from preclinical and in-vitro models only.
How is Semax related to ACTH(4-10)?
Semax is a synthetic analog built from the N-terminal portion of the ACTH(4-10) fragment of adrenocorticotropic hormone. It retains the Met-Glu-His-Phe sequence and adds a C-terminal Pro-Gly-Pro motif. This addition is reported to protect the peptide from rapid enzymatic degradation while removing the corticotropic, steroid-stimulating activity associated with the full hormone.
Does Semax affect BDNF levels?
Several rodent studies report that Semax increases BDNF protein and messenger RNA in regions such as the hippocampus and basal forebrain, along with changes in its receptor TrkB. This BDNF response is one of the most frequently cited findings in Semax mechanism research, though it has been characterized only in laboratory animal and cell models.
What is the difference between Semax and Selank?
Both are short synthetic Russian-developed neuropeptides that are studied for effects on BDNF and central nervous system signaling. Semax derives from an ACTH fragment and is examined mainly for neurotrophic and neuroprotective research, while Selank is a tuftsin analog studied more for GABAergic and anxiolytic-related pathways in animal models.
What is the molecular weight and sequence of Semax?
Semax is a heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro and the molecular formula C37H51N9O10S. Its approximate molecular weight is 813.9 grams per mole. These identity attributes are commonly reported for laboratory reference and comparison.
Is Semax available for human use?
No. Semax offered by research suppliers is intended for research use only, not for human consumption. Materials described here are handled as laboratory reference compounds, and any sourcing decision should be paired with a review of third-party testing such as a certificate of analysis.
References and Further Reading
- Dolotov O.V. and colleagues (2006), Institute of Molecular Genetics, Russian Academy of Sciences: research on Semax binding and brain-derived neurotrophic factor in the rat basal forebrain. PubMed: Semax BDNF basal forebrain
- Myasoedov N.F. and the Institute of Molecular Genetics group: foundational characterization of Semax as an ACTH(4-10) analog. PubMed: Semax ACTH analog
- Research on Semax and TrkB neurotrophin receptor signaling in preclinical models. PubMed: Semax TrkB
- Studies of Semax and nerve growth factor (NGF) expression. PubMed: Semax NGF
- Transcriptome and gene expression analyses of Semax in the hippocampus and under ischemic conditions (Limborska and colleagues). PubMed: Semax gene expression hippocampus
- Preclinical investigations of Semax in models of cerebral ischemia. PubMed: Semax cerebral ischemia
- Reviews of Semax as a regulatory neuropeptide within nootropic and neuroprotective research. PubMed: Semax neuropeptide
